WallStreetZenWallStreetZen

NASDAQ: INCY
Incyte Corp Stock

$57.12+0.57 (+1.01%)
Updated Mar 27, 2024
INCY Price
$57.12
Fair Value Price
$135.94
Market Cap
$12.82B
52 Week Low
$50.27
52 Week High
$76.04
P/E
21.39x
P/B
2.47x
P/S
3.8x
PEG
0.41x
Dividend Yield
N/A
Revenue
$3.70B
Earnings
$597.60M
Gross Margin
93.1%
Operating Margin
22.64%
Profit Margin
16.2%
Debt to Equity
0.31
Operating Cash Flow
$496M
Beta
0.63
Next Earnings
Apr 30, 2024
Ex-Dividend
N/A
Next Dividend
N/A

INCY Overview

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INCY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

INCY ($57.12) is undervalued by 57.98% relative to our estimate of its Fair Value price of $135.94 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
INCY ($57.12) is significantly undervalued by 57.98% relative to our estimate of its Fair Value price of $135.94 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
INCY ($57.12) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INCY due diligence checks available for Premium users.

Be the first to know about important INCY news, forecast changes, insider trades & much more!

INCY News

Valuation

INCY fair value

Fair Value of INCY stock based on Discounted Cash Flow (DCF)
Price
$57.12
Fair Value
$135.94
Undervalued by
57.98%
INCY ($57.12) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INCY ($57.12) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INCY ($57.12) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

INCY price to earnings (PE)

For valuing profitable companies with steady earnings
Company
21.39x
Industry
14.3x
Market
44.45x
INCY is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
INCY is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

INCY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.47x
Industry
6.2x
INCY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

INCY price to earnings growth (PEG)

For valuing profitable companies with growth potential
INCY is good value based... subscribe to Premium to read more.
PEG Value Valuation

INCY's financial health

Profit margin

Revenue
$1.0B
Net Income
$201.1M
Profit Margin
19.8%
INCY's Earnings (EBIT) of $836.77M... subscribe to Premium to read more.
Interest Coverage Financials
INCY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$6.8B
Liabilities
$1.6B
Debt to equity
0.31
INCY's short-term assets ($4.65B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INCY's short-term assets ($4.65B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INCY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INCY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$147.7M
Investing
-$154.5M
Financing
$346.0k
INCY's operating cash flow ($496.49M)... subscribe to Premium to read more.
Debt Coverage Financials

INCY vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
INCY$12.82B+1.01%21.39x2.47x
SRPT$12.22B+1.54%-22.45x14.22x
UTHR$11.45B-1.85%11.56x1.91x
TECH$10.91B+1.49%49.23x5.56x
LEGN$10.36B+1.84%-19.36x8.28x

Incyte Stock FAQ

What is Incyte's quote symbol?

(NASDAQ: INCY) Incyte trades on the NASDAQ under the ticker symbol INCY. Incyte stock quotes can also be displayed as NASDAQ: INCY.

If you're new to stock investing, here's how to buy Incyte stock.

What is the 52 week high and low for Incyte (NASDAQ: INCY)?

(NASDAQ: INCY) Incyte's 52-week high was $76.04, and its 52-week low was $50.27. It is currently -24.88% from its 52-week high and 13.63% from its 52-week low.

How much is Incyte stock worth today?

(NASDAQ: INCY) Incyte currently has 224,526,128 outstanding shares. With Incyte stock trading at $57.12 per share, the total value of Incyte stock (market capitalization) is $12.82B.

Incyte stock was originally listed at a price of $22.50 in Dec 31, 1997. If you had invested in Incyte stock at $22.50, your return over the last 26 years would have been 153.87%, for an annualized return of 3.65% (not including any dividends or dividend reinvestments).

How much is Incyte's stock price per share?

(NASDAQ: INCY) Incyte stock price per share is $57.12 today (as of Mar 27, 2024).

What is Incyte's Market Cap?

(NASDAQ: INCY) Incyte's market cap is $12.82B, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Incyte's market cap is calculated by multiplying INCY's current stock price of $57.12 by INCY's total outstanding shares of 224,526,128.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.